Regor
Therapeutics is a Massachusetts-based biotechnology company that develops and commercializes medicines for the treatment of cancer... Read moreRegor
Therapeutics is a Massachusetts-based biotechnology company that develops and commercializes medicines for the treatment of cancer... Read more
News
Jun 13, 2025
StreetInsider
Press Release: Regor : Regor to Present Data on its Lead Obesity Candidate, RGT-075, at the 85th Scientific Sessions of American Diabetes Association (ADA)
Mar 24, 2025
Yahoo
Regor: Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
Jan 13, 2025
Endpoints News
Regor: Regor's obesity pill posts muted weight loss in Phase 2a, enters new trial
Jan 10, 2025
PR Newswire
Press Release: Regor : Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
Oct 01, 2024
Zacks
Regor: Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
Jun 06, 2024
Marketscreener
Regor: Regor to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Mar 11, 2024
Pharmabiz
Regor: Regor initiates phase 2 study of oral oncedaily GLP1 agonist RGT075 to treat obesity
Feb 04, 2022
Drug Discovery and Development
Regor: Pfizer accuses former employees of trade secret theft
Dec 28, 2021
Markets Insider
Regor Therapeutics: Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
Dec 18, 2021
Global Legal Chronicle
Regor Therapeutics: Regor Therapeutics' Collaboration with Lilly